Understand this story
The English summary is being updated. See the reporting timeline below.
Latest development · Report
OpenAI Acquires Orchestra Bio, Merging It Into Life Sciences Platform RosalindDevelopments
1 confirmed developments
- Source:The Decoder
Reports and discussion timeline
Browse reports and discussion by time. Their evidence levels remain distinct.
Oct 21
The Decoder
OpenAI Acquires Orchestra Bio, Merging It Into Life Sciences Platform Rosalind
OpenAI has acquired Orchestra Bio, a startup that helps pharmaceutical companies coordinate drug development, and merged it into Rosalind, its AI platform for life sciences. Orchestra's agents can track clinical trials, flag affected timelines when problems such as failed batches arise, and present follow-up options. OpenAI says the move is aimed at building AI agents that connect scientific discovery with clinical trials and decision-making to speed new drugs to market; a new drug in the United States takes an average of 10 to 15 years to develop, and the deal amount was not disclosed.